Pioglitazone containing drugs 10 year epidemiology data has been submitted to US FDA and other Regulatory authorities Takeda pharmaceuticals.This action was a commitment for post-marketing data submission of Piolgitaozne .This study mainly designed to investigate whether patients who received pioglitazone were at an increased risk of bladder cancer.
According to the statistical data findings, there is no significant risk of bladder cancer among patients who were exposed to Pioglitazone.In addition,it was also found that there is no relation between duration of Piogiltazone use and risk of bladder cancer.
Pioglitazone is used in treatment of patients with diabetes mellitus type 2.This drug was first launched in 1999.
According to the statistical data findings, there is no significant risk of bladder cancer among patients who were exposed to Pioglitazone.In addition,it was also found that there is no relation between duration of Piogiltazone use and risk of bladder cancer.
Pioglitazone is used in treatment of patients with diabetes mellitus type 2.This drug was first launched in 1999.